Novo Nordisk announced it will reduce the prices of its weight-loss drugs Wegovy and Ozempic by up to 50%, effective January 2027, pricing them at $675 per month. This move comes amid increasing competition from other pharmaceutical companies like Eli Lilly, which markets Mounjaro and Zepbound. Novo Nordisk aims to improve affordability for patients, particularly those with high-deductible insurance plans, while maintaining its direct-to-patient pricing structure.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
